AtonRa Partners Reduces Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

AtonRa Partners cut its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 12.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 16,808 shares of the company’s stock after selling 2,364 shares during the quarter. AtonRa Partners’ holdings in Kymera Therapeutics were worth $428,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC increased its holdings in Kymera Therapeutics by 33.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,183 shares of the company’s stock worth $72,000 after acquiring an additional 1,310 shares during the period. Arizona State Retirement System bought a new position in Kymera Therapeutics in the 3rd quarter worth about $142,000. China Universal Asset Management Co. Ltd. increased its stake in Kymera Therapeutics by 352.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,423 shares of the company’s stock worth $164,000 after acquiring an additional 5,002 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Kymera Therapeutics in the 3rd quarter valued at about $185,000. Finally, Exchange Traded Concepts LLC boosted its position in shares of Kymera Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 7,359 shares of the company’s stock valued at $187,000 after acquiring an additional 1,866 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on KYMR. JPMorgan Chase & Co. upped their price objective on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Oppenheimer initiated coverage on shares of Kymera Therapeutics in a research report on Monday, April 22nd. They set an “outperform” rating and a $53.00 price objective on the stock. Bank of America lowered shares of Kymera Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the stock from $45.00 to $30.00 in a research report on Wednesday, January 3rd. Piper Sandler increased their target price on Kymera Therapeutics from $39.00 to $56.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. Finally, Truist Financial lifted their price target on Kymera Therapeutics from $41.00 to $54.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Six analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $41.20.

Kymera Therapeutics Trading Up 3.9 %

Shares of NASDAQ:KYMR traded up $1.29 on Monday, hitting $34.66. The company had a trading volume of 428,514 shares, compared to its average volume of 726,432. Kymera Therapeutics, Inc. has a 1 year low of $9.60 and a 1 year high of $45.31. The firm’s 50-day simple moving average is $38.91 and its two-hundred day simple moving average is $28.75.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.19. The company had revenue of $47.90 million for the quarter, compared to analyst estimates of $41.94 million. Kymera Therapeutics had a negative return on equity of 34.83% and a negative net margin of 187.00%. The firm’s revenue was up 197.5% on a year-over-year basis. During the same period in the previous year, the company posted ($0.60) earnings per share. Equities analysts predict that Kymera Therapeutics, Inc. will post -3.15 EPS for the current year.

Insider Transactions at Kymera Therapeutics

In related news, Director Bruce Booth sold 71,764 shares of the business’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $40.46, for a total transaction of $2,903,571.44. Following the sale, the director now owns 806,697 shares of the company’s stock, valued at $32,638,960.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, major shareholder Venture Fund X. L.P. Atlas sold 115,090 shares of the firm’s stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $42.23, for a total transaction of $4,860,250.70. Following the completion of the transaction, the insider now directly owns 4,676,075 shares in the company, valued at $197,470,647.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bruce Booth sold 71,764 shares of Kymera Therapeutics stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $40.46, for a total value of $2,903,571.44. Following the completion of the transaction, the director now directly owns 806,697 shares of the company’s stock, valued at approximately $32,638,960.62. The disclosure for this sale can be found here. Insiders have sold 474,051 shares of company stock valued at $19,624,211 in the last three months. 16.67% of the stock is currently owned by company insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.